Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models-Reference-Cited by-同舟云学术

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models

Published:2025 Issue: Volume:36 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Taya Manisha¹^ORCID,Hou Xiaonan²^ORCID,Veneris Jennifer T.³^ORCID,Kazi Nina¹^ORCID,Larson Melissa C.⁴^ORCID,Maurer Matthew J.⁴^ORCID,Heinzen Ethan P.⁵^ORCID,Chen Hao⁶^ORCID,Lastra Ricardo⁷^ORCID,Oberg Ann L.⁸^ORCID,Weroha S. John²^ORCID,Fleming Gini F.³^ORCID,Conzen Suzanne D.¹^ORCID

Affiliation:

1. Division of Hematology and Oncology, UT Southwestern, Dallas, TX, USA.

2. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

3. Department of Medicine, Section of Hematology and Oncology, The University of Chicago, Chicago, IL, USA.

4. Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.

5. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.

6. Department of Pathology, UT Southwestern, Dallas, TX, USA.

7. Department of Pathology, The University of Chicago, Chicago, IL, USA.

8. Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.

Funder

Mayo Clinic SPORE in Ovarian Cancer Developmental Research Program, Pilot Study Award

2017 Conquer Cancer Foundation/ASCO Young Investigator Award

Cancer Prevention Research Institute of Texas Recruitment of Established Investigators Award

The University of Chicago Women’s Board

National Cancer Institute

The University of Chicago Comprehensive Cancer Center

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2025.36.e4

Reference37 articles.

1. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

2. Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer

3. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions

4. Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer

5. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer